Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN: L85195TG1984PLC004507 | |
| Tel :+91 40 4900 2900 | |
| Fax :+91 40 4900 2999 | |
| Email :mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL)
Single-dose Vial in the U.S. Market"
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, | AMIT AGARWAL | MITALI SARKAR |
| Hyderabad - 500034. Telangana, India. | amita@drreddys.com | mitali.sarkar@drreddys.com |
| (Ph: +91-40-49002135) | (Ph: +91-40- 49002121) |
Reddy's Laboratories announces first-to-market
of Carboprost Tromethamine Injection USP,
mcg/mL (1mL) Single-dose Vial in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. July 3, 2019-
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as
"Dr. Reddy's") today announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose
Vial, a therapeutic equivalent generic version of Hemabate injection, 250 mcg/mL, approved by the U.S. Food and Drug Administration
"We are pleased to be first-to-market with this
product that has been designated as a Competitive Generic Therapy (CGT) by the FDA," says Marc Kikuchi, Chief Executive
Officer, North America Generics, Dr. Reddy's Laboratories. "With a CGT designation, we have 180-day CGT
exclusivity to market this product."
The Hemabate injection, 250 mcg/mL brand had U.S. sales
of approximately $55 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health*.
Dr. Reddy's Carboprost Tromethamine Injection USP, 250
mcg/mL (1mL) contains carboprost tromethamine equivalent to 250 mcg of carboprost.
| WARNINGS: |
| Carboprost Tromethamine Injection sterile solution (carboprost tromethamine) like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Carboprost Tromethamine Injection should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities. |
Hemabate is a trademark of Pfizer
*IQIA Retail and Non-Retail MAT May 2019
Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products
and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's
operates in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For
more information, log on to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views
and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to
differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason
of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events
(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization
, including related integration issues.
The company assumes no obligation to update any information